申请人:Otsuka Pharmaceutical Co., Ltd.
公开号:US04223137A1
公开(公告)日:1980-09-16
Carbostyril derivative represented by the formula (I): ##STR1## wherein R.sup.1 and R.sup.2, which may be the same or different, each represents a hydrogen atom, a cycloalkylcarbonyl group, a cycloalkylalkanoyl group, a benzoyl group, an alkanoyl group or a phenylalkylcarbonyl group; R.sup.4 represents a hydrogen atom or an alkyl group, R.sup.5 and R.sup.6, which may be the same or different, each represents a hydrogen atom, an alkyl group, a cycloalkyl group, or a phenylalkyl group, or R.sup.5 and R.sup.6 may, when taken together with the nitrogen atom to which they are attached, form a 5- or 6-membered substituted or unsubstituted heterocyclic ring containing 1 or 2 nitrogen or oxygen atoms as hetero atoms; and the ring A has a partial structure: ##STR2## wherein R.sup.3 represents a hydrogen atom, a cycloalkylcarbonyl group, a cycloalkylalkanoyl group, a benzoyl group, an alkanoyl group or a phenylalkylcarbonyl group, with the proviso that at least one of R.sup.1, R.sup.2 and R.sup.3 when R.sub.3 is present, or at least one of R.sub.1 and R.sub.2 when R.sub.3 is absent, represents a cycloalkylcarbonyl group, a cycloalkylalkanoyl group, a benzoyl group, an alkanoyl group or a phenylalkylcarbonyl group; the pharmaceutically acceptable acid addition salts of the above carbostyril compounds represented by the formula (I), and processes for preparing the above carbostyril compounds represented by the formula (I).
Carbostyril 衍生物由以下公式(I)表示:其中 R1 和 R2 可能相同也可能不同,分别代表氢原子、环烷基羰基、环烷基醇酰基、苯甲酰基、烷酰基或苯基烷基羰基;R4 代表氢原子或烷基;R5 和 R6 可能相同也可能不同,分别代表氢原子、烷基、环烷基或苯基烷基,或者 R5 和 R6 可以与它们连接的氮原子一起形成含有 1 或 2 个氮或氧原子作为杂原子的 5 或 6 个成员的取代或未取代杂环;环 A 具有部分结构:其中 R3 代表氢原子、环烷基羰基、环烷基醇酰基、苯甲酰基、烷酰基或苯基烷基,但至少当 R3 存在时,R1、R2 和 R3 中的至少一个,或当 R3 不存在时,R1 和 R2 中的至少一个代表环烷基羰基、环烷基醇酰基、苯甲酰基、烷酰基或苯基烷基;上述由公式(I)表示的 Carbostyril 化合物的药学上可接受的酸盐,以及制备上述由公式(I)表示的 Carbostyril 化合物的方法。